Thalidomide and celecoxib as potential modulators of irinotecan's activity in cancer patients.
Villalona-Calero M, Schaaf L, Phillips G, Otterson G, Panico K, Duan W, Kleiber B, Shah M, Young D, Wu WH, Kuhn J.
Villalona-Calero M, et al. Among authors: duan w.
Cancer Chemother Pharmacol. 2007 Jan;59(1):23-33. doi: 10.1007/s00280-006-0249-y. Epub 2006 May 10.
Cancer Chemother Pharmacol. 2007.
PMID: 16685529